OncoCyte Debt to Equity Ratio 2014-2023 | OCX
Current and historical debt to equity ratio values for OncoCyte (OCX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. OncoCyte debt/equity for the three months ending December 31, 2023 was 0.00.
| OncoCyte Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $0.05B | $0.02B | 2.66 |
| 2023-09-30 | $0.04B | $0.04B | 1.17 |
| 2023-06-30 | $0.04B | $0.04B | 1.01 |
| 2023-03-31 | $0.05B | $0.04B | 1.18 |
| 2022-12-31 | $0.07B | $0.03B | 1.92 |
| 2022-09-30 | $0.08B | $0.08B | 1.05 |
| 2022-06-30 | $0.09B | $0.08B | 1.06 |
| 2022-03-31 | $0.09B | $0.06B | 1.57 |
| 2021-12-31 | $0.09B | $0.07B | 1.45 |
| 2021-09-30 | $0.07B | $0.10B | 0.69 |
| 2021-06-30 | $0.08B | $0.10B | 0.73 |
| 2021-03-31 | $0.02B | $0.11B | 0.21 |
| 2020-12-31 | $0.02B | $0.03B | 0.66 |
| 2020-09-30 | $0.02B | $0.04B | 0.67 |
| 2020-06-30 | $0.02B | $0.04B | 0.60 |
| 2020-03-31 | $0.02B | $0.04B | 0.63 |
| 2019-12-31 | $0.01B | $0.03B | 0.29 |
| 2019-09-30 | $0.00B | $0.03B | 0.12 |
| 2019-06-30 | $0.00B | $0.03B | 0.12 |
| 2019-03-31 | $0.00B | $0.04B | 0.09 |
| 2018-12-31 | $0.01B | $0.00B | 1.78 |
| 2018-09-30 | $0.01B | $0.01B | 0.72 |
| 2018-06-30 | $0.01B | $0.01B | 0.78 |
| 2018-03-31 | $0.01B | $0.01B | 0.73 |
| 2017-12-31 | $0.01B | $0.00B | 1.32 |
| 2017-09-30 | $0.01B | $0.01B | 0.77 |
| 2017-06-30 | $0.01B | $0.01B | 1.15 |
| 2017-03-31 | $0.01B | $0.01B | 0.73 |
| 2016-12-31 | $0.01B | $0.01B | 0.47 |
| 2016-09-30 | $0.00B | $0.01B | 0.33 |
| 2016-06-30 | $0.00B | $0.00B | 0.66 |
| 2016-03-31 | $0.00B | $0.01B | 0.40 |
| 2015-12-31 | $0.00B | $0.01B | 0.22 |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2015-03-31 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.01B | $-0.00B | -5.90 |
| 2013-12-31 | $0.01B | $0.00B | 1.29 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.021B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $122.212B | 15.32 |
| Cencora (COR) | United States | $47.337B | 18.89 |
| ICON (ICLR) | Ireland | $24.074B | 23.75 |
| DiDi Global (DIDIY) | China | $22.638B | 0.00 |
| Avantor (AVTR) | United States | $16.482B | 22.71 |
| CochLear (CHEOY) | $13.356B | 0.00 | |
| Viatris (VTRS) | United States | $13.340B | 3.81 |
| Revvity (RVTY) | United States | $12.276B | 21.37 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.132B | 0.00 |
| Charles River Laboratories (CRL) | United States | $11.721B | 21.37 |
| Medpace Holdings (MEDP) | United States | $11.598B | 42.15 |
| Solventum (SOLV) | United States | $11.046B | 0.00 |
| Natera (NTRA) | United States | $10.540B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
| HealthEquity (HQY) | United States | $6.851B | 51.19 |
| Bausch + Lomb (BLCO) | Canada | $5.032B | 19.35 |
| Doximity (DOCS) | United States | $4.630B | 34.47 |
| Organon (OGN) | United States | $4.566B | 4.42 |
| Sotera Health (SHC) | United States | $3.085B | 15.14 |
| Progyny (PGNY) | United States | $3.064B | 51.42 |
| Surgery Partners (SGRY) | United States | $2.965B | 27.55 |
| Life Times (LTH) | United States | $2.756B | 30.46 |
| GoodRx Holdings (GDRX) | United States | $2.658B | 134.60 |
| Premier (PINC) | United States | $2.491B | 9.12 |
| Teladoc Health (TDOC) | United States | $2.232B | 0.00 |
| Agilon Health (AGL) | United States | $2.203B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.133B | 6.90 |
| BrightSpring Health Services (BTSG) | United States | $1.762B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.444B | 0.00 | |
| Agiliti (AGTI) | United States | $1.366B | 22.31 |
| NovoCure (NVCR) | Jersey | $1.297B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $0.964B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.740B | 7.66 |
| Embecta (EMBC) | United States | $0.596B | 3.94 |
| Auna S.A (AUNA) | Luxembourg | $0.549B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.544B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.522B | 0.00 |
| Enhabit (EHAB) | United States | $0.507B | 45.96 |
| MultiPlan (MPLN) | United States | $0.475B | 0.00 |
| Beauty Health (SKIN) | United States | $0.423B | 0.00 |
| CareDx (CDNA) | United States | $0.418B | 0.00 |
| LifeMD (LFMD) | United States | $0.412B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.391B | 0.00 |
| DocGo (DCGO) | United States | $0.356B | 57.00 |
| Sera Prognostics (SERA) | United States | $0.317B | 0.00 |
| ModivCare (MODV) | United States | $0.286B | 3.79 |
| Ascend Wellness Holdings (AAWH) | United States | $0.269B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.249B | 0.00 |
| Sharecare (SHCR) | United States | $0.227B | 0.00 |
| Biodesix (BDSX) | United States | $0.121B | 0.00 |
| So-Young (SY) | China | $0.119B | 40.00 |
| Oncology Institute (TOI) | United States | $0.091B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
| NeueHealth (NEUE) | United States | $0.052B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
| Nutex Health (NUTX) | United States | $0.033B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.029B | 0.00 |
| DermTech (DMTK) | United States | $0.020B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.016B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.015B | 0.00 | |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.013B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| OpGen (OPGN) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Assure Holdings (IONM) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |